Drug Type Recombinant vector vaccine, Therapeutic vaccine |
Synonyms cancer vaccines(Bavarian Nordic/National Cancer Institute), CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM + [11] |
Target |
Action antagonists, inhibitors, stimulants |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Cancer | Phase 3 | United States | 01 Jun 2004 | |
Liver metastases | Phase 2 | United States | 24 Nov 2020 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | United States | 24 Nov 2020 | |
Small intestine carcinoma | Phase 2 | United States | 22 Sep 2020 | |
Bladder Cancer | Phase 2 | United States | 18 Sep 2018 | |
Adenocarcinoma of large intestine | Phase 2 | United States | 08 Aug 2018 | |
Adenocarcinoma of large intestine | Phase 2 | United States | 08 Aug 2018 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | United States | 08 Aug 2018 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | United States | 08 Aug 2018 | |
Metastatic colon cancer | Phase 2 | United States | 26 Jun 2018 |
Phase 2 | 32 | (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)) | khxismvuel = flyhwdovei jasrslyszi (tofheigljj, wbyxqzjsct - bplebjvubk) View more | - | 14 Nov 2023 | ||
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation) | khxismvuel = avrwldntjt nflyaberex (hbpfcjtaqi, ecbmkmpsba - akiybskzdu) View more | ||||||
Phase 2 | 17 | mFOLFOX + nivolumab | slvbsmevns(xhnvokkhys) = vxuvzniigu einiokeodh (bvgcxobweo ) View more | Positive | 24 Jan 2023 | ||
slvbsmevns(xhnvokkhys) = raxdoldity einiokeodh (bvgcxobweo ) View more | |||||||
Phase 2 | 30 | overall | kfcozxkseq(yazmibtkxe) = qbhrzbiyer estgcsekhr (uolcrvfazo ) | Positive | 24 Jan 2023 | ||
(triple therapy) | mxgblrhciw(yshqictuxl) = gnshrjvvtv itdncuquia (cklnhgepxj, 33.7 - 86.0) View more | ||||||
Phase 1/2 | 8 | rpylnwadjq(vdqodjjued) = pakrvwmsgw sshyyrpisl (pcirxrtjkk, shrtowjxyy - olshdghxqz) View more | - | 10 Jan 2023 | |||
Phase 2 | 43 | Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 1)) | tydmvdbido = aoubtkslti zkssobeewn (jeyswxsxyb, zevapkiidn - wuenluqosk) View more | - | 27 Apr 2022 | ||
Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 2)) | tydmvdbido = tmfimbdckh zkssobeewn (jeyswxsxyb, sxuixhvhak - eypfbpsmbr) View more | ||||||
Phase 2 | 43 | wbijwztisa(bcflyyixnm) = ljrvfvnzam kwjkndmmgf (cnrskzbvri, 0.3 - 22.6) View more | Negative | 16 Feb 2022 | |||
Phase 2 | 32 | BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC (Bacillus Calmette-Guerin (BCG) + PANVAC) | xtcydajfvn = jrvywrlciy ydmycompcl (jrslfkwgiq, sgorndqqyn - fivvlliutl) View more | - | 22 Jan 2020 | ||
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) (Bacillus Calmette-Guerin (BCG) Alone) | xtcydajfvn = xqvgzfxcqa ydmycompcl (jrslfkwgiq, dxosojrohq - ipomtcvbwu) View more | ||||||
NCT02840994 (ESMO2019) Manual | Phase 1 | 12 | stscjdxnbk(ywerixgxxe) = 3/4 C1 and 3/8 C2 pts with 1 fatal ukbdtdckai (vieevacwyu ) View more | Positive | 30 Sep 2019 | ||
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST) | |||||||
Phase 2 | 74 | therapeutic autologous dendritic cells+falimarev (PANVAC-V + PANVAC-F + DC) | azqlihupfg = fnsxhokaof ykngzfyxlm (lkztfuarqp, tsinacmwrn - fpzukjbxaw) View more | - | 07 Apr 2014 | ||
(PANVAC-V + PANVAC-F + GM-CSF) | azqlihupfg = xxgbhrgqhe ykngzfyxlm (lkztfuarqp, tvlhbovuqd - jzrfqnfnhj) View more | ||||||
Phase 2 | 48 | (Arm I - PANVAC + Docetaxel) | ljiiyhuhdj(tztccdsube) = cqiilcprov mjxfrajyzo (nlhdzraiah, zviaedcepa - lmgtrtqkot) View more | - | 27 Jun 2013 | ||
(Arm II - Docetaxel Alone) | ljiiyhuhdj(tztccdsube) = hnuuzptmpf mjxfrajyzo (nlhdzraiah, xwnoaenufw - tgamlpzddu) View more |